Repurposing Drugs for Cancer Prevention

Area of Science:

• Oncology
• Pharmacology
• Preventive Medicine

Background:

• Cancer prevention agent development faces challenges due to target heterogeneity and the need for long-term, tolerable interventions.
• Advances in understanding cancer molecular pathogenesis offer new opportunities for early intervention before invasive disease.
• Drug repurposing is gaining interest for cancer prevention, leveraging existing agents with established mechanisms and safety profiles.

Purpose of the Study:

• To review the rationale and evidence for using aspirin, metformin, and pioglitazone as cancer prevention agents.
• To highlight the potential of repurposed drugs in early cancer intervention strategies.

Main Methods:

• Literature review of existing research on aspirin, metformin, and pioglitazone in cancer prevention.
• Analysis of the molecular mechanisms and clinical evidence supporting their use.

Main Results:

• Aspirin, metformin, and pioglitazone are currently prominent agents of interest in cancer prevention research.
• Evidence suggests these drugs may offer viable options for early intervention and cancer risk reduction.

Conclusions:

• Repurposing established drugs like aspirin, metformin, and pioglitazone presents a promising avenue for cancer prevention.
• Further research and clinical trials are warranted to confirm the effectiveness and optimize the use of these agents.